Megestrol Acetate
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00351 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | uterine corpus endometrial carcinoma | KG + DL |
| 2 | endometrial transitional cell carcinoma | KG + DL |
| 3 | hereditary breast ovarian cancer syndrome | KG + DL |
| 4 | borderline epithelial tumor of ovary | KG + DL |
| 5 | uterine carcinosarcoma | KG + DL |
| 6 | placenta cancer | KG + DL |
| 7 | ovarian clear cell adenocarcinoma | KG + DL |
| 8 | ovarian cancer | KG + DL |
| 9 | malignant dysgerminomatous germ cell tumor of ovary | KG + DL |
| 10 | low-grade neuroendocrine tumor of the corpus uteri | KG + DL |
| 11 | ovarian endometrioid stromal and related neoplasms | KG + DL |
| 12 | hereditary site-specific ovarian cancer syndrome | KG + DL |
| 13 | rete ovarii neoplasm | KG + DL |
| 14 | caudal duplication | KG + DL |
| 15 | maligant granulosa cell tumor of ovary | KG + DL |
| 16 | gonadal germ cell tumor | KG + DL |
| 17 | ovarian primitive germ cell tumor | KG + DL |
| 18 | familial ovarian cancer | KG + DL |
| 19 | exocrine pancreatic carcinoma | KG + DL |
| 20 | uterine corpus mixed epithelial and mesenchymal neoplasm | KG + DL |
| 21 | choriocarcinoma of ovary | KG + DL |
| 22 | high-grade neuroendocrine carcinoma of the corpus uteri | KG + DL |
| 23 | uterine corpus choriocarcinoma | KG + DL |
| 24 | colorectal cancer, hereditary nonpolyposis, | KG + DL |
| 25 | uterine corpus adenosarcoma | KG + DL |
| 26 | uterine corpus adenocarcinofibroma | KG + DL |
| 27 | primitive neuroectodermal tumor of the corpus uteri | KG + DL |
| 28 | pancreatic neoplasm | KG + DL |
| 29 | ovarian cancer, susceptibility to, 1 | KG + DL |
| 30 | ovarian adenosarcoma | KG + DL |
| 31 | papillary carcinoma of the corpus uteri | KG + DL |
| 32 | transitional cell carcinoma of the corpus uteri | KG + DL |
| 33 | malignant pancreatic neoplasm | KG + DL |
| 34 | gonadoblastoma | KG + DL |
| 35 | ovarian gynandroblastoma | KG + DL |
| 36 | rare variants of adenocarcinoma of the corpus uteri | KG + DL |
| 37 | endometrium carcinoma in situ | KG + DL |
| 38 | endometrioid stromal sarcoma | KG + DL |
| 39 | Muir-Torre syndrome | KG + DL |
| 40 | adenoid cystic carcinoma of the corpus uteri | KG + DL |
| 41 | malignant germ cell tumor of corpus uteri | KG + DL |
| 42 | hyperplastic polyposis syndrome | KG + DL |
| 43 | ovarian gonadoblastoma (disease) | KG + DL |
| 44 | ovarian malignant mesothelioma | KG + DL |
| 45 | uterine corpus carcinofibroma | KG + DL |
| 46 | ovarian neoplasm | KG + DL |
| 47 | malignant ovarian cyst | KG + DL |
| 48 | prostate cancer/brain cancer susceptibility | KG + DL |
| 49 | malignant non-epithelial tumor of ovary | KG + DL |
| 50 | ovarian endometrioid adenocarcinofibroma | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.